Search
BioCardia Inc
BCDAAdd to Watchlist
1.240USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
13.34MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+24.00%
1 Month
+33.33%
6 Months
-0.80%
Year to Date
-0.80%
1 Year
-36.41%
Key Figures
1.220Open
1.255High
134.43KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.25%Turnover Ratio
1.240Prev. Close
1.200Low
77.24KTurnover
LossP/E Static
14.90P/B
0.00%Div Yield TTM
-400.98%ROA
2.45052wk High
0.13Volume Ratio
-7.95MNet Profit
10.76MShares
-0.8581EPS TTM
0.51Beta
-950.12%ROE
0.84052wk Low
4.44%Amplitude
100.00%Gross Margin
13.34MMarket Cap
7.97Reward/Risk
4.36%Risk Rate
TradingKey Stock Score of BioCardia Inc
Currency: USD Updated: 2026-06-30Key Insights
BioCardia Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 136 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioCardia Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
BioCardia Inc Highlights
StrengthsRisks
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Undervalued
The company’s latest PE is -1.45, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 737.78K shares, increasing 26.65% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 18.68K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.60.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
15.500
Target Price
+1180.99%
Upside Space
BioCardia Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioCardia Inc Info
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Ticker SymbolBCDA
CompanyBioCardia Inc
CEOAltman (Peter)
Websitehttps://www.biocardia.com/
Related Instruments
-0.55%
-0.70%
-2.70%
-0.89%
-1.56%
-1.27%
-0.37%
+2.71%
-0.15%
-0.71%
+0.78%
-1.50%
-2.17%
-2.73%
+0.87%
0.00%
+0.80%
-2.75%
-0.12%
-0.41%Popular Instruments
52656.700
+460.400 (+0.88%)
30000.000
-224.600 (-0.74%)
7518.200
+35.800 (+0.48%)
15376.000
-219.000 (-1.40%)
69994.000
-862.000 (-1.22%)
6289.800
-37.200 (-0.59%)
68.058
-1.863 (-2.66%)
294.920
+5.560 (+1.92%)
197.060
-3.030 (-1.51%)
4085.170
+77.890 (+1.94%)
FAQs
What is the current price of BioCardia Inc (BCDA)?
The current price of BioCardia Inc (BCDA) is 1.24.
What is the symbol of BioCardia Inc?
The ticker symbol of BioCardia Inc is BCDA.
What is the 52-week high of BioCardia Inc?
The 52-week high of BioCardia Inc is 2.45.
What is the 52-week low of BioCardia Inc?
The 52-week low of BioCardia Inc is 0.84.
What is the market capitalization of BioCardia Inc?
The market capitalization of BioCardia Inc is 18.46M.
Is BioCardia Inc (BCDA) currently rated as Buy, Hold, or Sell?
According to analysts, BioCardia Inc (BCDA) has an overall rating of Buy, with a price target of 15.50.
What is the Earnings Per Share (EPS TTM) of BioCardia Inc (BCDA)?
The Earnings Per Share (EPS TTM) of BioCardia Inc (BCDA) is -1.23.